SEC Form 4 · accession 0001104659-26-073461
Nuvectis Pharma, Inc. · NVCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Hoberman
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 4:12 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001875558
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 11, 2026 | A | 35,000 | $0.00 | A | 168,140 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates.
- F2Includes shares of restricted common stock.